{"id":11973,"date":"2026-03-12T14:55:08","date_gmt":"2026-03-12T14:55:08","guid":{"rendered":"https:\/\/medical-article.com\/?p=11973"},"modified":"2026-03-12T14:55:08","modified_gmt":"2026-03-12T14:55:08","slug":"operational-efficiencies-of-using-one-vs-multiple-bispecific-antibodies-for-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma-in-the-us","status":"publish","type":"post","link":"https:\/\/medical-article.com\/?p=11973","title":{"rendered":"Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US"},"content":{"rendered":"<p>That is the title of a new paper published in <em>Future Oncology<\/em> with co-authors Tara Graff,Savreet Bains Chawla,Monika Jun,Nicole Heaps,Abualbishr Alshreef,David Tybor,Donald C. Moore,Nadine Zawadzki, and Kathryn Spurrier.  The abstract is below: <\/p>\n<h3>Aim<\/h3>\n<p><em>To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) compared with using two separate single-indication therapies.<\/em><\/p>\n<h3>Materials &amp; methods<\/h3>\n<p><em>The study conducted a national survey of clinicians (oncologists, pharmacists, nurses\/physician assistants) treating non-Hodgkin lymphoma (NHL) patients in the US to quantify the impact of operational efficiencies identified through formative qualitative interviews with oncology staff. Quantitative analysis estimated time-savings based on survey data, assuming one new prescription per patient per year and 12 (DLBCL) and 15 (FL) administration visits per patient per year. Time-savings were combined with staff wage rates to estimate cost-savings.<\/em><\/p>\n<h3>Results<\/h3>\n<p><em>Among n\u2009=\u2009105 respondents, drivers of operational efficiencies included onboarding, coordinating insurance and financial aid, and medication preparation. For a hypothetical community practice treating 100 bsAb-eligible patients (61% DLBCL, 39% FL), total time-savings were 3110\u00a0h in the first year of adoption, resulting in total monetized time-savings of $278,013. For a hypothetical academic practice, monetized time-savings were $963,074 in the first year of adoption.<\/em><\/p>\n<h3>Conclusions<\/h3>\n<p><em>Using a single bsAb to treat R\/R DLBCL and FL is predicted to lead to considerable time- and cost-savings for oncology practices.<\/em><\/p>\n<p>You can read the full paper <a href=\"https:\/\/www.tandfonline.com\/doi\/10.1080\/14796694.2026.2636559#abstract\">here<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>That is the title of a new paper published in Future Oncology with co-authors Tara Graff,Savreet Bains Chawla,Monika Jun,Nicole Heaps,Abualbishr Alshreef,David Tybor,Donald C. Moore,Nadine Zawadzki, and Kathryn Spurrier. The abstract is below: Aim To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed\/refractory (R\/R) diffuse&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-11973","post","type-post","status-publish","format-standard","hentry","category-articles"],"_links":{"self":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/11973"}],"collection":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11973"}],"version-history":[{"count":0,"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/11973\/revisions"}],"wp:attachment":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}